drugset / Trial / NCT02285920

Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD Trial

NCT02285920

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The SPin-D Trial is a phase II randomized, double-blind, placebo-controlled, multi-center study of spironolactone (SPL) for patients with hemodialysis-dependent end-stage renal disease.

Timeline

Start
2014-11
Primary completion
2017-06
Completion
2017-07-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Spironolactone Small molecule 12.5 mg
Comparator Spironolactone Small molecule 25 mg
Comparator Spironolactone Small molecule 50 mg